Related Experiment Video
Updated: Mar 23, 2026
11:38
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents HPHC
Published on: May 10, 2016
12.8K
[Alpha-1 Antitrypsin Affects U0126-Induced Cytotoxicity in Colon Cancer Cell Line (HCT116)]
M Ljujic1, S Mijatovic2, M Z Bulatovic2
1Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Molekuliarnaia Biologiia
|March 31, 2016
Summary
Alpha-1-antitrypsin (AAT) protects colon cancer cells from death by maintaining autophagy, a process that counteracts apoptosis. This finding offers insights into AAT
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Alpha-1-antitrypsin (AAT) is a key circulatory anti-protease with potential as a tumor marker.
- Its specific role in cancer biology and its anti-apoptotic effects on cancer cells are largely unknown.
- Previous studies indicated AAT possesses anti-apoptotic properties in non-malignant cells.
Purpose of the Study:
- To investigate the effect of Alpha-1-antitrypsin (AAT) on apoptosis in the HCT116 colon cancer cell line.
- To determine if AAT influences cell viability when exposed to inhibitors of key signaling pathways.
Main Methods:
- Utilized the HCT116 colon cancer cell line.
- Administered AAT in combination with pathway inhibitors (MEK1/2, PI3K/Akt, NF-κB).
- Assessed cell viability and apoptosis induction, focusing on the role of autophagy.
Main Results:
- AAT antagonized the cytotoxicity of MEK1/2, PI3K/Akt, and NF-κB pathway blockers in HCT116 cells.
- Co-treatment with AAT and the MEK1/2 inhibitor U0126 significantly recovered cell viability.
- AAT abolished U0126-induced apoptosis by sustaining the autophagy process.
Conclusions:
- Alpha-1-antitrypsin (AAT) confers cyto-protection in colon cancer cells by maintaining autophagy, which opposes apoptosis.
- This study elucidates a novel mechanism for AAT's role in cancer cell survival.
- Findings may inform the understanding of AAT in cancer development and therapeutic strategies.
Related Concept Videos
01:19Allosteric Proteins-ATCase
6.9K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.9K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
66
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66